---
id: bacteroides-fragilis-anaerobic-infections_075
category: organisms
tags: [bacteroides-fragilis, anaerobic-infections, metronidazole, intra-abdominal-infection, brain-abscess]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Bacteroides fragilis & Anaerobic Infections

**Q:** What are the clinical syndromes, resistance patterns, and treatment strategies for Bacteroides fragilis and other anaerobic infections?

**A:**

**Microbiology:**
- **Gram-negative anaerobic bacillus** (Bacteroidetes phylum)
- **Most common anaerobic pathogen** in clinical infections
- **Part of normal GI flora** (10^11 organisms/g stool)
- Produces **capsular polysaccharide** (virulence factor → abscess formation)
- Produces **β-lactamase** (>90% isolates) → penicillin resistance

**Other Important Anaerobic Bacteria:**
- **Bacteroides species:** B. thetaiotaomicron, B. ovatus, B. uniformis
- **Prevotella species:** Oral/gynecologic infections
- **Porphyromonas species:** Oral infections
- **Fusobacterium necrophorum:** Lemierre syndrome
- **Clostridium species** (covered separately)
- **Anaerobic cocci** (Peptostreptococcus, Finegoldia - covered separately)

---

**Risk Factors for Anaerobic Infection:**
- **Disruption of mucosal barriers:**
  - GI perforation, surgery, trauma
  - Aspiration (pneumonia)
  - Dental procedures
- **Tissue ischemia/necrosis:**
  - Diabetes, vascular disease
  - Malignancy
  - Foreign body
- **Prior antibiotic exposure** (alters normal flora)

---

**Clinical Syndromes:**

**1. Intra-Abdominal Infections (Most Common):**

**Peritonitis:**
- Secondary to GI perforation (appendicitis, diverticulitis, bowel ischemia)
- **Polymicrobial:** Anaerobes (Bacteroides, Clostridium) + Enterobacterales (E. coli)

**Intra-Abdominal Abscess:**
- Liver abscess (pyogenic)
- Splenic abscess
- Peritoneal abscess

**Biliary Tract Infections:**
- Cholangitis, cholecystitis (polymicrobial)

**Key Point:** **Bacteroides fragilis = #1 anaerobe in intra-abdominal infections**

---

**2. Brain Abscess:**

**Epidemiology:**
- **Anaerobes in 60-80% of brain abscesses**
- Often **polymicrobial** (anaerobes + Streptococcus, Staphylococcus)

**Sources:**
- **Contiguous spread:** Sinusitis, otitis, mastoiditis, dental infection
- **Hematogenous:** Endocarditis, bacteremia
- **Trauma/Neurosurgery**

**Common Anaerobic Pathogens:**
- **Bacteroides fragilis**
- **Prevotella species**
- **Fusobacterium species**
- **Anaerobic cocci** (Peptostreptococcus)

**Key Point:** **Always cover anaerobes empirically** in brain abscess

---

**3. Aspiration Pneumonia & Lung Abscess:**

**Microbiology:**
- **Polymicrobial:** Anaerobes (oral flora) + aerobes
- **Anaerobes:** Prevotella, Fusobacterium, Peptostreptococcus

**Risk Factors:**
- Altered consciousness (seizure, alcohol, stroke)
- Dysphagia
- Poor dentition

**Key Point:** **Anaerobes from oral flora** (NOT GI Bacteroides)

---

**4. Pelvic Infections:**

**Tubo-Ovarian Abscess:**
- Polymicrobial: Anaerobes (Bacteroides, Prevotella) + aerobes (E. coli, Strep)

**Endometritis:**
- Postpartum, post-abortion

**Bacterial Vaginosis:**
- **NOT an infection** (overgrowth of anaerobes)
- Gardnerella vaginalis, Prevotella, Mobiluncus

---

**5. Skin/Soft Tissue Infections:**

**Necrotizing Fasciitis (Type I):**
- **Polymicrobial:** Anaerobes + facultative bacteria
- Fournier gangrene (perineum)

**Diabetic Foot Infection:**
- Polymicrobial (including anaerobes if deep/necrotic)

---

**6. Lemierre Syndrome (Fusobacterium necrophorum):**

**Definition:**
- **Post-pharyngitis septic thrombophlebitis** of internal jugular vein

**Microbiology:**
- **Fusobacterium necrophorum** (anaerobic Gram-negative bacillus)
- Primarily affects **young, healthy adults** (15-30 years)

**Clinical Features:**
- **Pharyngitis** (often after)
- **Neck pain/swelling** (internal jugular vein thrombosis)
- **Septicemia** (fever, rigors)
- **Septic emboli** (lungs, joints, liver)

**Diagnosis:**
- Blood cultures: **Fusobacterium necrophorum**
- CT neck: **Internal jugular vein thrombophlebitis**

**Treatment:**
- **Antibiotics:** Metronidazole + β-lactam OR carbapenem (see below)
- **Anticoagulation:** Controversial (consider if extension/CNS involvement)
- Duration: 4-6 weeks

**Key Point:** **Young healthy adult + pharyngitis + neck pain + septic emboli = Lemierre**

---

**Diagnosis:**

**Culture:**
- **Requires anaerobic culture media** (blood culture bottles detect most)
- Transport specimens immediately (anaerobes die with oxygen exposure)
- **Foul-smelling pus = anaerobes** (volatile fatty acids)

**Imaging:**
- CT/MRI for abscess identification
- Brain abscess: Ring-enhancing lesion

---

**Treatment:**

**Key Principle:** **Anaerobic coverage + source control** (drainage, surgery)

---

**1. First-Line Agents:**

**A. Metronidazole:**

**Dosing:**
- **Metronidazole** 500 mg IV/PO q8h OR 1g IV q12h

**Spectrum:**
- **Excellent activity** against Bacteroides fragilis (<1% resistance)
- Covers all obligate anaerobes

**Limitations:**
- **Poor activity** against aerobic Gram-positives (Streptococcus, Enterococcus)
- **Must combine with aerobic coverage** for polymicrobial infections

**B. β-Lactam/β-Lactamase Inhibitor Combinations:**

| **Agent** | **Dosing** | **Spectrum** |
|-----------|------------|--------------|
| **Ampicillin-sulbactam** | 3g IV q6h | B. fragilis (good), but ~15-20% resistance ↑ |
| **Piperacillin-tazobactam** | 3.375g IV q6h OR 4.5g IV q6-8h | Excellent B. fragilis coverage + Pseudomonas |
| **Amoxicillin-clavulanate** | 875 mg PO BID OR 2g IV q6h | Good oral option (PO step-down) |
| **Ticarcillin-clavulanate** | 3.1g IV q4-6h | Rarely used (replaced by pip-tazo) |

**Key Point:** **Piperacillin-tazobactam = preferred** for polymicrobial intra-abdominal infections

**C. Carbapenems:**

| **Agent** | **Dosing** | **Anaerobic Coverage** |
|-----------|------------|------------------------|
| **Ertapenem** | 1g IV q24h | Excellent (NOT Pseudomonas) |
| **Meropenem** | 1g IV q8h | Excellent + Pseudomonas |
| **Imipenem-cilastatin** | 500 mg IV q6h | Excellent + Pseudomonas |
| **Doripenem** | 500 mg IV q8h | Excellent + Pseudomonas |

**Key Point:** **100% activity** against Bacteroides fragilis

**D. Tigecycline:**

**Dosing:**
- **Tigecycline** 100 mg IV x1, then 50 mg IV q12h

**Spectrum:**
- Excellent anaerobic coverage + ESBL, MRSA
- **Black box warning:** ↑ mortality (vs comparators in meta-analyses)
- Reserve for **limited options only**

---

**2. Agents With Variable/Poor Activity Against Anaerobes:**

**❌ Poor/No Activity:**
- **Aminoglycosides** (gentamicin, tobramycin, amikacin) - require oxygen for uptake
- **Aztreonam** (no anaerobic activity)
- **Fluoroquinolones** (ciprofloxacin, levofloxacin) - variable, not reliable
- **TMP-SMX** - poor anaerobic activity
- **Cephalosporins (most):**
  - Cefazolin, ceftriaxone, cefepime: **NO Bacteroides coverage**
  - **Exception:** **Cefoxitin** (has anaerobic activity - but rarely used)

**✅ Some Activity (But NOT First-Line):**
- **Clindamycin:**
  - Good for **oral/dental anaerobes** (Prevotella, Fusobacterium)
  - **Increasing B. fragilis resistance** (15-30% in US) → NOT recommended for intra-abdominal
- **Moxifloxacin:**
  - Better anaerobic activity than other FQs
  - Acceptable alternative (not first-line)

---

**3. Treatment by Syndrome:**

**Intra-Abdominal Infection (Complicated):**

**Empiric Regimen (Community-Acquired, Mild-Moderate):**
- **Ceftriaxone** 1-2g IV q24h PLUS **Metronidazole** 500 mg IV q8h
- OR **Ertapenem** 1g IV q24h (monotherapy)
- OR **Piperacillin-tazobactam** 3.375g IV q6h (monotherapy)

**Empiric Regimen (Healthcare-Associated, Severe, or High ESBL Risk):**
- **Meropenem** 1g IV q8h OR **Imipenem** 500 mg IV q6h
- OR **Piperacillin-tazobactam** 4.5g IV q6h

**Duration:**
- **4-7 days** (after source control + clinical improvement)
- Longer if inadequate source control

**Source Control ESSENTIAL:**
- Drainage (percutaneous or surgical)
- Resection of necrotic tissue

---

**Brain Abscess:**

**Empiric Regimen (Contiguous Spread - Sinusitis/Otitis/Dental):**
- **Ceftriaxone** 2g IV q12h PLUS **Metronidazole** 500 mg IV q8h PLUS **Vancomycin** 15-20 mg/kg IV q8-12h

**Rationale:**
- **Ceftriaxone:** Streptococcus (viridans, pneumoniae)
- **Metronidazole:** Anaerobes (Bacteroides, Prevotella, Fusobacterium)
- **Vancomycin:** MRSA (if post-neurosurgery or trauma)

**Empiric Regimen (Hematogenous - Endocarditis):**
- **Vancomycin** + **Ceftriaxone** + **Metronidazole**

**Duration:**
- **4-8 weeks IV** (at least 4-6 weeks)
- Guided by clinical/imaging response

**Drainage:**
- Consider **stereotactic aspiration** if >2.5 cm or expanding

---

**Aspiration Pneumonia / Lung Abscess:**

**Empiric Regimen:**
- **Ampicillin-sulbactam** 3g IV q6h (preferred - covers oral anaerobes)
- OR **Clindamycin** 600 mg IV q8h (alternative)
- OR **Metronidazole** + **β-lactam** (ceftriaxone or cefepime)

**Duration:**
- Pneumonia: 7-10 days
- Lung abscess: **3-4 weeks** (until cavity resolution)

**Drainage:**
- Usually not needed (antibiotics sufficient)
- Bronchoscopy if large abscess/non-response

---

**Pelvic Infections (Tubo-Ovarian Abscess, Endometritis):**

**Empiric Regimen:**
- **Cefoxitin** 2g IV q6h + **Doxycycline** 100 mg IV/PO BID
- OR **Clindamycin** 900 mg IV q8h + **Gentamicin** 5-7 mg/kg IV q24h
- OR **Ampicillin-sulbactam** 3g IV q6h + **Doxycycline** 100 mg IV/PO BID

**Outpatient (Mild):**
- **Ceftriaxone** 500 mg IM x1 PLUS **Doxycycline** 100 mg PO BID x 14 days PLUS **Metronidazole** 500 mg PO BID x 14 days

**Duration:**
- Until afebrile 48h, then switch to PO (total 14 days)

---

**Lemierre Syndrome:**

**Empiric Regimen:**
- **Metronidazole** 500 mg IV q8h + **Ceftriaxone** 2g IV q24h
- OR **Meropenem** 1g IV q8h OR **Piperacillin-tazobactam** 3.375g IV q6h

**Duration:**
- **4-6 weeks** (bacteremia + thrombophlebitis)

---

**Resistance Patterns:**

**Bacteroides fragilis Resistance (US):**
- **Metronidazole:** <1% resistance (excellent)
- **Carbapenems:** <1% resistance (excellent)
- **Piperacillin-tazobactam:** 3-5% resistance (good)
- **Ampicillin-sulbactam:** 15-20% resistance (↑ over time)
- **Clindamycin:** 15-30% resistance (DO NOT use empirically)
- **Cefoxitin:** 10-15% resistance

**Mechanism:**
- **cfiA gene:** Carbapenem resistance (rare, but emerging)
- **β-lactamases:** Universal (>90%)

---

**Source Control:**

**Key Principle:** **Antibiotics alone INSUFFICIENT** without source control

**Source Control Methods:**
- **Drainage:** Percutaneous (CT/US-guided) or surgical
- **Resection:** Necrotic tissue, perforated viscus
- **Device removal:** If foreign body infection

**Timing:**
- **As soon as possible** (within 12-24h for peritonitis)
- Delayed source control → ↑ mortality

---

**Mnemonic: "FAME for Anaerobes"**
- **F**ragilis = most common (B. fragilis)
- **A**bscess formation (capsular polysaccharide)
- **M**etronidazole = first-line
- **E**liminate source (drainage essential)

**Mnemonic: "FOUL = Anaerobes"**
- **F**oul-smelling pus
- **O**bligate anaerobes
- **U**sually polymicrobial
- **L**ocation matters (GI → Bacteroides, oral → Prevotella)

**Clinical Pearls:**
- **Foul-smelling pus = anaerobes** (volatile fatty acids)
- **Bacteroides fragilis = #1 anaerobe** in intra-abdominal infections
- **Metronidazole <1% resistance** for B. fragilis (excellent choice)
- **Clindamycin NOT recommended** for B. fragilis (15-30% resistance)
- **Source control ESSENTIAL** (antibiotics alone fail without drainage)
- **Brain abscess ALWAYS cover anaerobes** (60-80% have anaerobes)
- **Aspiration pneumonia:** Oral anaerobes (Prevotella, Fusobacterium) - NOT GI Bacteroides
- **Lemierre syndrome:** Young adult + pharyngitis + neck pain + septic emboli
- **Aminoglycosides INEFFECTIVE** (require oxygen for uptake)
- **Ceftriaxone/cefepime NO anaerobic activity** (must add metronidazole)
- **Carbapenems = 100% activity** against Bacteroides fragilis

**Media:** None

**Sources:** [IDSA 2024 - Intra-abdominal infection guidelines], [IDSA 2017 - Brain abscess treatment], [PMC 2024 - Bacteroides fragilis pathogenesis], [Clinical Infectious Diseases 2024 - Anaerobic resistance trends], [Mandell's Principles 9th edition - Anaerobic infections], [IDSA 2021 - Aspiration pneumonia], [PMC 2023 - Lemierre syndrome review]
